Academic Journals Database
Disseminating quality controlled scientific knowledge

CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: PRESENT STANDARDS

ADD TO MY LIST
 
Author(s): L. Miron | M. Marinca

Journal: jurnalul de chirurgie (journal of surgery)
ISSN 1584-9341

Volume: 3;
Issue: 2;
Start page: 110;
Date: 2007;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: ADVANCED GASTRIC CANCER | SURGERY | CHEMOTHERAPY | RESULTS

ABSTRACT
Despite a sharp decline of its incidence during the second half of the 20th century, gastric cancer remains the second leading cause of cancer mortality in the world. Most gastric cancer patients are diagnosed when the tumor is inoperable. For these patients, systemic chemotherapy remains the main treatment option. Although a large number of chemotherapy regimens have been tested in randomized studies, there is no globally accepted standard of care, and uncertainty regarding the choice of the regimen persists. Irrespective of the positive impact of any presently available chemotherapy, the prognosis of patients with advanced gastric cancer remains desperate, with a median survival of only 7 to 10 months in most larger clinical studies. The best survival results are achieved with three-drug regimens containing 5-fluorouracil, an anthracycline and cisplatin. Future applications of newer cytotoxic drugs, targeted therapies and integration of molecular determinants of tumor behavior, prognosis and response to therapy may ultimately help to improve current standards and facilitate the delivery of more tailored and efficient therapeutic interventions.
Why do you need a reservation system?      Affiliate Program